• Je něco špatně v tomto záznamu ?

Health-related quality of life in women with autoimmune thyroid disease during pregnancy and postpartum: systematic review including 321,850 pregnancies

J. Tuzil, J. Bartakova, T. Watt, T. Dolezal

. 2021 ; 21 (6) : 1179-1193. [pub] 20210820

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, systematický přehled

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011808

BACKGROUND: Utilities of the general population or expert estimates have been used for all published cost-effectiveness analyses of screening for thyroid disorders in pregnancy. METHODS: A systematic review CRD42019120897 of studies with patient-reported outcomes (PRO) and laboratory evidence of thyroid function/autoimmunity was conducted using PubMed, Cochrane Central, EconLit, SocIndex, DARE, NHS EEDS, Annual Reviews, and CINAHL. Quality was assessed using Joanna Briggs Institute appraisal tool. RESULTS: Of 664 abstracts screened, we analyzed 97 full texts. All studies describing the impact of thyroid disease on the generic QoL excluded pregnant and postpartum women. 21 reports of acceptable quality (321,850 pregnancies) determined depression and anxiety with validated tools and/or reported subjective symptoms. During pregnancy, contradictory conclusions were published on the impact of thyroid disease on PRO. Postpartum, antithyroid antibodies coincide with alexithymia and depression, postpartum thyroiditis negatively impacts mood. No conclusion could be drawn on the impact of thyroid hormonal levels. CONCLUSIONS: The generic QoL in autoimmune thyroid disease during pregnancy has never been described, which represents an obstacle for the construction of economic models. We found contradictory information on the impact of thyroid disease on depression, anxiety, and specific symptoms.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011808
003      
CZ-PrNML
005      
20220506130831.0
007      
ta
008      
220425s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/14737167.2021.1941882 $2 doi
035    __
$a (PubMed)34120552
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Tuzil, Jan $u Department of Biomedical Informatics, First Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute of Health Economics and Technology Assessment o.p.s (iHETA), Prague, Czech Republic $1 https://orcid.org/0000000271824010
245    10
$a Health-related quality of life in women with autoimmune thyroid disease during pregnancy and postpartum: systematic review including 321,850 pregnancies / $c J. Tuzil, J. Bartakova, T. Watt, T. Dolezal
520    9_
$a BACKGROUND: Utilities of the general population or expert estimates have been used for all published cost-effectiveness analyses of screening for thyroid disorders in pregnancy. METHODS: A systematic review CRD42019120897 of studies with patient-reported outcomes (PRO) and laboratory evidence of thyroid function/autoimmunity was conducted using PubMed, Cochrane Central, EconLit, SocIndex, DARE, NHS EEDS, Annual Reviews, and CINAHL. Quality was assessed using Joanna Briggs Institute appraisal tool. RESULTS: Of 664 abstracts screened, we analyzed 97 full texts. All studies describing the impact of thyroid disease on the generic QoL excluded pregnant and postpartum women. 21 reports of acceptable quality (321,850 pregnancies) determined depression and anxiety with validated tools and/or reported subjective symptoms. During pregnancy, contradictory conclusions were published on the impact of thyroid disease on PRO. Postpartum, antithyroid antibodies coincide with alexithymia and depression, postpartum thyroiditis negatively impacts mood. No conclusion could be drawn on the impact of thyroid hormonal levels. CONCLUSIONS: The generic QoL in autoimmune thyroid disease during pregnancy has never been described, which represents an obstacle for the construction of economic models. We found contradictory information on the impact of thyroid disease on depression, anxiety, and specific symptoms.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a poporodní období $7 D049590
650    _2
$a těhotenství $7 D011247
650    12
$a kvalita života $7 D011788
650    12
$a autoimunitní tyreoiditida $7 D013967
655    _2
$a časopisecké články $7 D016428
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Bartakova, Jana $u Department of Biomedical Informatics, First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department Public Health, Faculty of Medicine, University of Basel, Basel, Switzerland
700    1_
$a Watt, Torquil $u Department of Internal Medicine, Endocrinology, Herlev Gentofte Hospital, Copenhagen, Denmark $1 https://orcid.org/0000000260017440
700    1_
$a Dolezal, Tomas $u Institute of Health Economics and Technology Assessment o.p.s (iHETA), Prague, Czech Republic $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
773    0_
$w MED00174435 $t Expert review of pharmacoeconomics & outcomes research $x 1744-8379 $g Roč. 21, č. 6 (2021), s. 1179-1193
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34120552 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130823 $b ABA008
999    __
$a ok $b bmc $g 1789423 $s 1163006
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 21 $c 6 $d 1179-1193 $e 20210820 $i 1744-8379 $m Expert review of pharmacoeconomics & outcomes research $n Expert rev. pharmacoecon. outcomes res. $x MED00174435
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace